Common mucus drug tested as new hope for fatty liver
NCT ID NCT07242222
Summary
This study is testing whether a medication called erdosteine, often used for mucus in lung conditions, can help treat nonalcoholic fatty liver disease (NAFLD). It will involve 50 adult patients with NAFLD to see if the drug safely reduces fat buildup and scarring in the liver. The main goal is to see if it improves liver health as seen on an ultrasound.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.